Strs Ohio Purchases 1,300 Shares of NantKwest, Inc. (NASDAQ:NK)

Strs Ohio grew its position in NantKwest, Inc. (NASDAQ:NK) by 21.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,500 shares of the biotechnology company’s stock after purchasing an additional 1,300 shares during the quarter. Strs Ohio’s holdings in NantKwest were worth $52,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in NK. Bank of Montreal Can bought a new position in shares of NantKwest in the second quarter valued at approximately $32,000. FNY Investment Advisers LLC acquired a new stake in shares of NantKwest in the third quarter worth $41,000. Point72 Hong Kong Ltd acquired a new stake in shares of NantKwest in the third quarter worth $48,000. BNP Paribas Arbitrage SA grew its stake in shares of NantKwest by 522.8% in the third quarter. BNP Paribas Arbitrage SA now owns 7,231 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 6,070 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of NantKwest in the third quarter worth $51,000. 9.22% of the stock is currently owned by institutional investors.

NK opened at $13.33 on Friday. NantKwest, Inc. has a fifty-two week low of $2.52 and a fifty-two week high of $19.37. The firm’s fifty day moving average price is $10.83 and its two-hundred day moving average price is $9.77. The company has a market capitalization of $1.45 billion, a P/E ratio of -18.77 and a beta of 2.52.

In other news, Director John C. Thomas sold 42,592 shares of the business’s stock in a transaction on Thursday, December 10th. The shares were sold at an average price of $10.83, for a total value of $461,271.36. Following the sale, the director now owns 207,477 shares in the company, valued at approximately $2,246,975.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Barry J. Simon sold 130,000 shares of the business’s stock in a transaction on Tuesday, December 22nd. The shares were sold at an average price of $18.05, for a total transaction of $2,346,500.00. Following the completion of the sale, the insider now owns 3,300,540 shares in the company, valued at approximately $59,574,747. The disclosure for this sale can be found here. 72.08% of the stock is owned by insiders.

Several equities research analysts have recently issued reports on NK shares. BidaskClub downgraded shares of NantKwest from a “hold” rating to a “sell” rating in a research note on Friday, October 23rd. Zacks Investment Research upgraded shares of NantKwest from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 14th.

About NantKwest

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Further Reading: How does a margin account work?